Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration

BackgroundIntervertebral disc degeneration (IDD) significantly contributes to low back pain (LBP), yet effective treatment options are scarce. BSHXF, a classical traditional Chinese medicine formula, demonstrates dual pharmacological actions: tonifying kidneys, strengthening bones, activating blood...

Full description

Saved in:
Bibliographic Details
Main Authors: Enxu Liu, Yu Sun, Lei Yang, Haobo Jiang, Fei Sun, Long Chen, Jiahao Duan, Shaofeng Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1583635/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850175614846238720
author Enxu Liu
Enxu Liu
Yu Sun
Yu Sun
Lei Yang
Lei Yang
Haobo Jiang
Haobo Jiang
Fei Sun
Long Chen
Jiahao Duan
Jiahao Duan
Shaofeng Yang
Shaofeng Yang
author_facet Enxu Liu
Enxu Liu
Yu Sun
Yu Sun
Lei Yang
Lei Yang
Haobo Jiang
Haobo Jiang
Fei Sun
Long Chen
Jiahao Duan
Jiahao Duan
Shaofeng Yang
Shaofeng Yang
author_sort Enxu Liu
collection DOAJ
description BackgroundIntervertebral disc degeneration (IDD) significantly contributes to low back pain (LBP), yet effective treatment options are scarce. BSHXF, a classical traditional Chinese medicine formula, demonstrates dual pharmacological actions: tonifying kidneys, strengthening bones, activating blood circulation, and resolving stasis. It has been widely used in IDD management. Given its potential, combining BSHXF with miRNA regulation and stem cell therapy may enhance therapeutic outcomes by targeting molecular and cellular pathways underlying IDD pathogenesis.Aim of the studyIDD is recognized as one of the primary causes of low back pain, yet effective therapeutic interventions for this condition remain limited. This study explores the role of BSHXF drug-containing serum combined with adipose-derived stem cells (ADSCs) in slowing IDD progression via the miR-199a-3p/TGF-β/Smad signaling pathway. By comprehensively investigating the synergistic effects of this combination therapy, we aim to propose a novel multi-target strategy that addresses the complex pathogenesis of IDD.Materials and MethodsThis study employed a combination of in vivo and in vitro models. An IDD model was induced in rat caudal intervertebral discs through needle puncture, while an oxidative stress-induced ADSCs injury model was created in vitro using tert-butyl hydroperoxide (T-BHP). Cell viability was measured with the CCK-8 assay. Cell cycle distribution and mitochondrial reactive oxygen species (ROS) levels were assessed using flow cytometry. Cellular senescence was assessed using SA-β-galactosidase staining. Lactate dehydrogenase (LDH) activity was quantified to evaluate cellular damage. Differentiation into nucleus pulposus-like cells was assessed using immunofluorescence double staining for CD73 and COL2A1. ELISA was used to measure inflammatory cytokines (TNF-α, IL-1β, IL-4, IL-10) in cell supernatants. miR-199a-3p expression was determined using RT-qPCR. Western blotting was employed to quantify COL2A1, SOX9, and ACAN protein levels, reflecting nucleus pulposus-like differentiation and extracellular matrix (ECM) synthesis capacity. Western blotting was employed to assess pathway activity by analyzing the protein expressions of TGF-β1, Smad2, Smad3, and their phosphorylated forms, P-Smad2 and P-Smad3. In vivo experiments assessed histopathological degeneration through hematoxylin-eosin (HE) and Safranin O-Fast Green staining. Immunohistochemistry (IHC) analyzed COL1A1 and COL2A1 expression levels. RT-qPCR quantified miR-199a-3p expression. Western blotting was employed to assess the expression levels of TGF-β1, Smad2, Smad3, P-Smad2, and P-Smad3 for pathway regulation evaluation.ResultsOur experimental results demonstrated that serum containing BSHXF significantly alleviated T-BHP-induced oxidative stress, improved the cellular microenvironment, promoted ADSCs proliferation, and decelerated cellular senescence. Further mechanistic analysis revealed that BSHXF significantly activated the TGF-β/Smad signaling pathway, driving the differentiation of ADSCs into nucleus pulposus-like cells and restoring normal cell cycle progression. Overexpression of miR-199a-3p inhibited the TGF-β/Smad pathway, leading to ECM degradation and elevated expression of inflammatory factors (TNF-α, IL-1β). In contrast, BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression. In vivo experiments demonstrated that miR-199a-3p overexpression exacerbated IDD, characterized by reduced COL2A1 expression, elevated COL1A1 levels, and increased disc fibrosis. BSHXF intervention markedly attenuated IDD progression by downregulating miR-199a-3p expression, reducing disc fibrosis, and effectively restoring collagen expression.ConclusionBSHXF activated the TGF-β/Smad pathway to promote the differentiation of ADSCs into nucleus pulposus-like cells. It exerted protective effects by alleviating oxidative stress damage, improving the microenvironment, delaying senescence, and enhancing cellular functions. This study is the first to reveal that miR-199a-3p overexpression exacerbates intervertebral disc fibrosis and degeneration. BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression, thereby improving disc structure and function. This integrated approach offers a novel multi-target intervention strategy for IDD, demonstrating significant therapeutic potential.
format Article
id doaj-art-4c376ffdbf2c45f6bf8369149c799fa4
institution OA Journals
issn 1663-9812
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-4c376ffdbf2c45f6bf8369149c799fa42025-08-20T02:19:26ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-04-011610.3389/fphar.2025.15836351583635Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degenerationEnxu Liu0Enxu Liu1Yu Sun2Yu Sun3Lei Yang4Lei Yang5Haobo Jiang6Haobo Jiang7Fei Sun8Long Chen9Jiahao Duan10Jiahao Duan11Shaofeng Yang12Shaofeng Yang13Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaHunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaHunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaHunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaHunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaHunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaHunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, ChinaThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, ChinaBackgroundIntervertebral disc degeneration (IDD) significantly contributes to low back pain (LBP), yet effective treatment options are scarce. BSHXF, a classical traditional Chinese medicine formula, demonstrates dual pharmacological actions: tonifying kidneys, strengthening bones, activating blood circulation, and resolving stasis. It has been widely used in IDD management. Given its potential, combining BSHXF with miRNA regulation and stem cell therapy may enhance therapeutic outcomes by targeting molecular and cellular pathways underlying IDD pathogenesis.Aim of the studyIDD is recognized as one of the primary causes of low back pain, yet effective therapeutic interventions for this condition remain limited. This study explores the role of BSHXF drug-containing serum combined with adipose-derived stem cells (ADSCs) in slowing IDD progression via the miR-199a-3p/TGF-β/Smad signaling pathway. By comprehensively investigating the synergistic effects of this combination therapy, we aim to propose a novel multi-target strategy that addresses the complex pathogenesis of IDD.Materials and MethodsThis study employed a combination of in vivo and in vitro models. An IDD model was induced in rat caudal intervertebral discs through needle puncture, while an oxidative stress-induced ADSCs injury model was created in vitro using tert-butyl hydroperoxide (T-BHP). Cell viability was measured with the CCK-8 assay. Cell cycle distribution and mitochondrial reactive oxygen species (ROS) levels were assessed using flow cytometry. Cellular senescence was assessed using SA-β-galactosidase staining. Lactate dehydrogenase (LDH) activity was quantified to evaluate cellular damage. Differentiation into nucleus pulposus-like cells was assessed using immunofluorescence double staining for CD73 and COL2A1. ELISA was used to measure inflammatory cytokines (TNF-α, IL-1β, IL-4, IL-10) in cell supernatants. miR-199a-3p expression was determined using RT-qPCR. Western blotting was employed to quantify COL2A1, SOX9, and ACAN protein levels, reflecting nucleus pulposus-like differentiation and extracellular matrix (ECM) synthesis capacity. Western blotting was employed to assess pathway activity by analyzing the protein expressions of TGF-β1, Smad2, Smad3, and their phosphorylated forms, P-Smad2 and P-Smad3. In vivo experiments assessed histopathological degeneration through hematoxylin-eosin (HE) and Safranin O-Fast Green staining. Immunohistochemistry (IHC) analyzed COL1A1 and COL2A1 expression levels. RT-qPCR quantified miR-199a-3p expression. Western blotting was employed to assess the expression levels of TGF-β1, Smad2, Smad3, P-Smad2, and P-Smad3 for pathway regulation evaluation.ResultsOur experimental results demonstrated that serum containing BSHXF significantly alleviated T-BHP-induced oxidative stress, improved the cellular microenvironment, promoted ADSCs proliferation, and decelerated cellular senescence. Further mechanistic analysis revealed that BSHXF significantly activated the TGF-β/Smad signaling pathway, driving the differentiation of ADSCs into nucleus pulposus-like cells and restoring normal cell cycle progression. Overexpression of miR-199a-3p inhibited the TGF-β/Smad pathway, leading to ECM degradation and elevated expression of inflammatory factors (TNF-α, IL-1β). In contrast, BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression. In vivo experiments demonstrated that miR-199a-3p overexpression exacerbated IDD, characterized by reduced COL2A1 expression, elevated COL1A1 levels, and increased disc fibrosis. BSHXF intervention markedly attenuated IDD progression by downregulating miR-199a-3p expression, reducing disc fibrosis, and effectively restoring collagen expression.ConclusionBSHXF activated the TGF-β/Smad pathway to promote the differentiation of ADSCs into nucleus pulposus-like cells. It exerted protective effects by alleviating oxidative stress damage, improving the microenvironment, delaying senescence, and enhancing cellular functions. This study is the first to reveal that miR-199a-3p overexpression exacerbates intervertebral disc fibrosis and degeneration. BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression, thereby improving disc structure and function. This integrated approach offers a novel multi-target intervention strategy for IDD, demonstrating significant therapeutic potential.https://www.frontiersin.org/articles/10.3389/fphar.2025.1583635/fullintervertebral disc degenerationmiR-199a-3p/TGF-β/Smad signaling pathwayadipose-derived stem cellsoxidative stressextracellular matrix synthesis
spellingShingle Enxu Liu
Enxu Liu
Yu Sun
Yu Sun
Lei Yang
Lei Yang
Haobo Jiang
Haobo Jiang
Fei Sun
Long Chen
Jiahao Duan
Jiahao Duan
Shaofeng Yang
Shaofeng Yang
Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration
Frontiers in Pharmacology
intervertebral disc degeneration
miR-199a-3p/TGF-β/Smad signaling pathway
adipose-derived stem cells
oxidative stress
extracellular matrix synthesis
title Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration
title_full Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration
title_fullStr Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration
title_full_unstemmed Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration
title_short Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration
title_sort investigating the regulation of the mir 199a 3p tgf β smad signaling pathway by bshxf drug containing serum combined with adscs for delaying intervertebral disc degeneration
topic intervertebral disc degeneration
miR-199a-3p/TGF-β/Smad signaling pathway
adipose-derived stem cells
oxidative stress
extracellular matrix synthesis
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1583635/full
work_keys_str_mv AT enxuliu investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT enxuliu investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT yusun investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT yusun investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT leiyang investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT leiyang investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT haobojiang investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT haobojiang investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT feisun investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT longchen investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT jiahaoduan investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT jiahaoduan investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT shaofengyang investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration
AT shaofengyang investigatingtheregulationofthemir199a3ptgfbsmadsignalingpathwaybybshxfdrugcontainingserumcombinedwithadscsfordelayingintervertebraldiscdegeneration